Drugs / AB-1001
AB-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05541627 | Oct 2022 → Apr 2024 overdue | Huntington disease | AskBio Inc | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05541627 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated viral vector serotype Rh10” NCT05541627 ↗ |
| Route | Other | “One-time intracerebral bilateral injections” NCT05541627 ↗ |
| Target | CYP46A1 | “One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene” NCT05541627 ↗ |